UAE治疗不同类型症状性子宫肌瘤中期疗效及安全性研究

目的 探讨子宫动脉栓塞术(UAE)治疗不同类型症状性子宫肌瘤中期临床疗效和安全性。方法 回顾性分析行UAE治疗的33例患者的临床资料,分析患者术后月经评分、临床有效率、不良反应及并发症,比较术前和术后6个月肌瘤体积缩小率、月经量减少率,比较术前和术后6个月不同类型症状性子宫肌瘤的疗效。结果 UAE治疗子宫肌瘤疗效确切,术前和术后6个月肌瘤体积缩小率、月经量减少率差异均有统计学意义(P<0.05)。对不同类型子宫肌瘤治疗效果无明显差异(P>0.05)。术后无严重不良反应及并发症发生。结论 UAE治疗症状性子宫肌瘤安全有效,对不同类型子宫肌瘤疗效无差异,在保留子宫的同时能显著缓解患者临床症状。     

影响子宫肌瘤栓塞治疗的因素

目的观察子宫动脉栓塞术(UAE)对子宫肌瘤的治疗效果,并分析影响疗效的因素。方法46例症状性子宫肌瘤患者经超选择性插管双侧子宫动脉内注入PVA微粒栓塞治疗,术后6、9个月随访复查,观察临床症状改善,肌瘤体积变化情况,并对临床上治疗效果与多种不同的影响因素进行分析。结果UAE术后临床症状改善,尤其以子宫出血症状改善最为明显,栓塞后6个月肌瘤体积平均缩小45.6%,9个月肌瘤体积平均缩小58.4%。盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等因素影响子宫肌瘤栓塞后的疗效。结论双侧子宫动脉栓塞治疗子宫肌瘤是一种安全、有效的方法,其疗效与盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等多种因素有关。     

子宫动脉栓塞术治疗子宫肌瘤的临床研究

目的评价子宫动脉栓塞术（UAE）治疗子宫肌瘤的临床效果。方法对49例经临床、超声或MRI诊断为子宫肌瘤的患者行UAE，采用Seldinger技术经股动脉穿刺，将导管选择性插入双侧子宫动脉，经导管注入聚乙稀醇颗粒（PVA）、海藻酸钠微球（KMG）或明胶海绵微粒栓塞，阻断肌瘤供血动脉。术后定期观察月经量、一般症状、子宫与病灶体积变化。结果术后所有患者临床症状均有明显改善或消失，月经恢复正常，子宫肌瘤均有不同程度的缩小，无严重并发症发生。结论动脉栓塞治疗子宫肌瘤是一种微创性的治疗手段，可使肌瘤进行性缩小，临床症状改善，是子宫肌瘤临床治疗的又一种选择。     

动脉栓塞术治疗子宫肌瘤远期疗效的观察

目的:探讨子宫动脉栓塞术(UAE)治疗子宫肌瘤的远期疗效。方法:37例子宫肌瘤患者行子宫动脉栓塞术,平均随访3年。结果:子宫肌瘤血供丰富,均为双侧子宫动脉供血,一侧为主,4例卵巢动脉参与供血,供血动脉粗大、迂曲,在瘤体的周围及内部形成血管网、团,瘤体染色明显。术后随访B超显示肌瘤缩小明显、临床症状改善,有效率达100%,无1例复发。结论:子宫动脉栓塞术治疗于宫肌瘤是一种高效、微创、安全且经济的方法,远期疗效好,值得临床应用推广。     

子宫肌瘤介入治疗前后CT动态扫描血供变化的研究

目的 研究子宫肌瘤介入治疗前后子宫与肌瘤血供变化。方法 16例单发症状性子宫肌瘤患者接受子宫动脉栓塞治疗，术前、术后7d及术后3个月选择同层面进行CT动态增强扫描，测量正常子宫及肌瘤的CT值，进行栓塞前后对比分析。结果 16例患者每次均顺利完成CT动态增强扫描，术前、术后7d及术后3个月正常子宫组织动态增强曲线及CT值无明显改变，而肌瘤动态增强曲线及CT值有明显改变，肌瘤栓塞后处于持续性缺血状态。结论 子宫动脉栓塞术治疗子宫肌瘤是一种安全，有效的新疗法，子宫动脉栓塞后非肌瘤子宫组织血供不受影响。     

经导管子宫动脉栓塞治疗症状性子宫肌瘤的临床观察

目的:探讨经导管子宫动脉栓塞术(UAE)治疗症状性子宫肌瘤的临床疗效及副反应。方法:选择有明显临床症状的32例子宫肌瘤患者,运用Seldinger技术超选择性子宫动脉插管,以平阳霉素碘油乳剂进行栓塞,术后3个月、6个月、8个月1、2个月观察疗效。结果:32例患者在术后随访12个月,子宫体积平均缩小60.6%,肌瘤体积平均缩小76.3%。所有病例,月经恢复正常,贫血改善,压迫症状基本消失,未出现严重并发症。结论:UAE治疗症状性子宫肌瘤是一种疗效显著、安全性高的微创治疗方法。     

子宫动脉栓塞治疗子宫肌瘤对女性激素的影响

目的 探讨子宫动脉栓塞术(UAE)治疗子宫肌瘤对女性分泌功能的影响.方法 31例子宫肌瘤患者行UAE后随访3～6个月,观察月经变化及监测血清卵泡刺激素(FSH)、黄体生成素(LH)、孕酮(Prog)、雌二醇(E2)4种性激素变化.同时于介入手术前及术后3、6个月分别行B超检查测定肌瘤体积及肌瘤的供血状况.结果 25例(80.6%)UAE后恢复正常月经,临床症状明显改善,4例(12.9%)有一过性月经紊乱(3～6个月恢复正常),2例(0.06%)出现闭经(年龄45岁、49岁).31例患者4种血清性激素术前、术后变化差异无统计学意义(P＞0.05).结论 UAE是一种有效的治疗手段,对女性血清性激素无明显影响,但年龄大于45岁以上者可能出现闭经.     

子宫动脉栓塞治疗子宫肌壁间肌瘤的疗效及安全性

目的探讨子宫动脉栓塞术（UAE）治疗子宫肌壁间肌瘤的疗效及安全性。方法 2012年1～12月收治28例经超声确诊的子宫肌壁间肌瘤患者,行UAE治疗,观察术后疗效、并发症及安全性。结果 28例随访9～21个月,月经量较术前减少,痛经症状缓解或消失,贫血改善。其中21例子宫肌瘤消失,7例子宫肌瘤体积明显缩小。术中、术后出现不同程度腹痛25例,术后发热14例,阴道分泌物增多10例,所有患者经对症处理后,症状均在3～7 d内逐渐消失。无一例出现闭经。结论 UAE治疗子宫肌壁间肌瘤疗效显著、微创、安全性高。     

子宫动脉栓塞治疗子宫肌瘤的生命质量评价

目的　评价子宫动脉栓塞治疗子宫肌瘤的生命质量变化 ,并与手术治疗相比较。方法按照完全随机对照研究方法 ,将子宫肌瘤患者分为子宫动脉栓塞组和手术治疗组 ,术前和术后 6个月进行生命质量问卷调查 ,分析治疗前后 2组患者生命质量的变化。结果　 2 79例症状性子宫肌瘤患者符合标准进入本研究 ,其中栓塞组 1 39例 ,手术组 1 4 0例。 2 1 8例患者 (栓塞组 1 1 8例 ,手术组1 0 0例 )完成术后 6个月的生命质量问卷。栓塞组术后的生命质量各因子评分均较术前明显提高 ,差异均有非常显著性意义 (P <0 0 0 1 ) ,而手术组术后除性生活评分与术前比较差异无显著性意义外 ,其他因子评分与术前相比差异均有非常显著性意义 (P <0 0 0 1 ) ;治疗前后生命质量评分差值两组患者相比较 ,术后性生活、一般健康状况、精力、情感职能和精神健康和健康变化等因子评分差值两组差异均有显著性意义 (P <0 0 0 1 ) ,栓塞组高于手术组。结论　子宫动脉栓塞比手术治疗更能提高子宫肌瘤患者的术后生命质量     

超声在海藻酸钠微球栓塞治疗子宫肌瘤中的应用

目的探讨二维及彩色多普勒超声在评价新型栓塞剂海藻酸钠微球(KMG)用于子宫动脉栓塞(UAE)治疗子宫肌瘤近期疗效中的价值。方法49例子宫肌瘤患者在应用KMG经UAE术前3～7d及其后1、3、6个月进行二维及彩色多普勒超声检查,观察其二维声像图、血流动力学变化。结果栓塞6个月后肌瘤体积明显缩小(缩小35%～90%),早期瘤内回声明显增强,后出现液性暗区、钙化等改变,术后肌瘤内血流完全消失。结论KMG是一种有效的用于UAE治疗子宫肌瘤的栓塞剂,而超声对评价其效果、不良反应及术后的长期随访具有重要价值,是无创性检查的首选方法。     

Mid-term Clinical Results and Patient Satisfaction After Uterine Artery Embolization in Women with Symptomatic Uterine Fibroids

Purpose To evaluate the mid-term clinical results and patient satisfaction following uterine artery embolization (UAE) in women with symptomatic fibroids. Methods Between August 1998 and December 2002, 135 patients had UAE for symptomatic uterine fibroids. All patients were asked to fill in a questionnaire. Questions were aimed at changes in bleeding, pain, and bulk-related symptoms. Symptoms after UAE were scored as disappeared, improved, unchanged or worsened. Adverse events were noted, such as vaginal dryness and discharge, menopausal complaints or fibroid expulsion. Patient satisfaction after UAE was assessed. Patient satisfaction of women embolized with polyvinyl alcohol (PVA) particles was compared with satisfaction of women embolized with calibrated microspheres. Results The questionnaire was returned by 110 of 135 women (81%) at a median time interval of 14 months following UAE. In 10 women additional embolization or hysterectomy had been performed. Of the 110 responders, 86 (78%) were satisfied with the result of UAE. The proportion of satisfied women was higher in the group embolized with calibrated microspheres than in women embolized with PVA, although this difference was not statistically significant (p = 0.053). Conclusion UAE in women with symptomatic uterine fibroids leads to improvement of symptoms and patient satisfaction is good in the vast majority after a median follow-up period of 14 months.     

Uterine Artery Embolization in 101 Cases of Uterine Fibroids: Do Size, Location, and Number of Fibroids Affect Therapeutic Success and Complications?

The purpose of this study was to evaluate whether the size, location, or number of fibroids affects therapeutic efficacy or complications of uterine artery embolization (UAE). Patients with symptomatic uterine fibroids (n = 101) were treated by selective bilateral UAE using 500- to 710-μm polyvinyl alcohol (PVA) particles. Baseline measures of clinical symptoms, sonography, and MRI taken before the procedure were compared to those taken 1, 3, 6, and 12 months later. Complications and outcomes were analyzed for associations with fibroid size, location, and number. Reductions in mean fibroid volume were similar in patients with single (66.6 ± 21.5%) and multiple (67.4 ± 25.0%) fibroids (p-value = 0.83). Menstrual improvement occurred in patients with single (93.3%) and multiple (72.2%) fibroids (p = 0.18). Changes in submucosal and other fibroids were not significantly different between the two groups (p’s > 0.56). Linear regression analysis between primary fibroid volume as independent variable and percentage reduction of fibroid volume after 1 year yielded an R² of 0.083 and the model coefficient was not statistically significant (p = 0.072). Multivariate regression models revealed no statistically or clinically significant coefficients or odds ratios for three independent variables (primary fibroid size, total number, and fibroid location) and all outcome variables (percent reduction of uterus and fibroid volumes in 1 year, improvement of clinical symptoms [menstrual, bulk related, and urinary] in 1 year, and complications after UAE). In conclusion, neither the success rate nor the probability of complications was affected by the primary fibroid size, location, or total number of fibroids.     

Langzeitergebnisse nach Myomembolisation

Fibroids (leiomyoma) are the most frequent benign tumors of the uterus during female reproductive age. In the case of clinical symptoms, uterine artery embolization (UAE) is a well established treatment option for symptomatic fibroids, resulting in promising long-term results. In order to estimate long-term success after UAE, reduction of fibroids and uterus volume is less important than complete improvement and disappearance of fibroid-related symptoms. In addition to a high technical success rate and a low perioperative complication rate, UAE results in high short-term and long-term patient satisfaction (>87%) and improvement of symptoms (>81%). Candidates for UAE should be informed about potential reinterventions in terms of repeated UAE (up to 18% of cases) or surgical treatment options.     

Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up

PURPOSE: To evaluate clinical and magnetic resonance (MR) imaging results after uterine artery embolization (UAE) in women with symptomatic adenomyosis with or without uterine leiomyomas. MATERIALS AND METHODS: Thirty-eight women with symptomatic adenomyosis with or without uterine leiomyomas were treated with UAE with calibrated tris-acryl gelatin microspheres. Based on MR findings, women were categorized as having pure adenomyosis (group A; n = 15), adenomyosis dominance with fibroid tumors (group B; n = 14), or fibroid tumor dominance with adenomyosis (group C; n = 9). RESULTS: Heavy menstrual bleeding, pain, and bulk-related symptoms at last follow-up at a median of 16.5 months (range, 3-38 months) were compared with baseline symptoms. With follow-up MR imaging at a median of 12 months (range, 3-36 months), changes in uterine volume, leiomyoma volume, junctional zone thickness, and contrast enhancement of adenomyosis were assessed. After embolization, adenomyosis infarction could be depicted on contrast medium-enhanced MR in 44.1% of cases. Median reductions of uterine volume, fibroid tumor volume, and junctional zone thickness were 44.8%, 77.1%, and 23.9%, respectively. In group A, three patients needed additional surgery after UAE, in addition to two in group B and one in group C. In the remaining 32 patients, except for one patient in group C, all preexisting symptoms (eg, bleeding, pain, bulk-related symptoms) improved or resolved after UAE. Overall, 84.2% of women were satisfied with the results of UAE. CONCLUSION: In this study, midterm results (at a median of 16.5 months) showed that UAE in symptomatic adenomyosis with or without uterine leiomyomas is effective. Hysterectomy was avoided in the vast majority of patients. MR imaging showed reduction of uterine volume and junctional zone thickness.     

子宫肌瘤栓塞术后产生疼痛的临床防治

目的 探讨子宫肌瘤栓塞术后产生疼痛的防治措施。方法 56例子宫肌瘤患者栓塞术后均出现疼痛，按对栓塞术后产生疼痛的处理方法不同分为对症组与预防组，分别为3l例和25例。通过观察2组患者术后疼痛的程度和持续时间，评价2种处理方法有无差异。结果 2组患者发生不同程度疼痛的比例无明显差异，但疼痛持续时间预防组显著较短。结论 积极地做好预防处理能有效地减轻子宫肌瘤栓塞术后产生疼痛的程度和持续时间，提高介入治疗的综合效果。     

超声在子宫肌瘤的子宫动脉栓塞术疗效评价中的价值

目的:探讨超声在子宫动脉栓塞术治疗子宫肌瘤术后疗效随访中的应用价值。材料和方法:58例子宫肌瘤患者分别在栓塞术前1周、术后1个月、6个月、12个月运用超声观察子宫大小形态、肌瘤大小形态和血流动力学的改变。结果:术后1个月子宫体积平均缩小44.24%,肌瘤体积平均缩小43.74%;术后6个月子宫体积平均缩小62.72%,肌瘤体积平均缩小61.25%;术后1年子宫体积平均缩小72.17%,肌瘤体积平均缩小70.18%。其中以单发肌瘤、内膜肌瘤患者疗效明显,肌瘤的血供较术前明显减少。结论:超声在评价子宫动脉栓塞术治疗子宫肌瘤术后疗效中有重要价值。     

Mid- and long-term quality-of-life assessment in patients undergoing uterine fibroid embolization

OBJECTIVE: Our objective was to assess the mid- and long-term outcomes concerning fibroid-specific and fibroid-associated quality of life in patients treated by uterine fibroid embolization. MATERIALS AND METHODS: A retrospective cohort study was performed, including consecutive patients with a minimum follow-up of 1 year. Analysis was performed by a questionnaire consisting of 49 questions about six topics: baseline characteristics, preinterventional status, diagnostic workup and treatment planning, periinterventional period and procedure-related quality of life, follow-up, and general satisfaction. RESULTS: The analysis was performed based on questionnaires from 53 (85.5%) of 62 patients. The mean follow-up was 3.0 +/- 1.0 (SD) years (range, 1.0-5.0 years). Uterine fibroid embolization led to a reduction of bleeding symptoms in 79.2% of patients (n = 48 before uterine fibroid embolization; n = 10 after uterine fibroid embolization), pain in 81.5% (n = 27; n = five, respectively), bulk-related symptoms in 78.6% (n = 14; n = three, respectively), urinary dysfunction in 60% (n = 10; n = four, respectively), sexual dysfunction in 71.4% (n = seven; n = two, respectively), fatigue in 62.5% (n = 24; n = nine, respectively), limitations in social life in 88.2% (n = 17; n = two, respectively), and a depressed mood in 89.5% (n = 19; n = two, respectively). The median impairment score for bleeding and pain decreased significantly from 6 to 0 and from 4 to 0, respectively (both p < 0.001). The general quality-of-life index increased significantly from 6 to 9 (p < 0.001). Forty-two (79.2%) patients judged the result as very satisfactory and would highly recommend uterine fibroid embolization to other patients. CONCLUSION: Uterine fibroid embolization leads to an impressive mid- and long-term improvement of all investigated physical and psychological fibroid-related and fibroid-associated symptoms and significantly improves women's health-related quality of life.